浙贝母散剂逆转急性白血病多药耐药的临床研究

目的初步探讨浙贝母散剂和化疗合用时是否能起到逆转P170高表达的作用及其临床应用前景.方法.应用流式细胞仪检测急性白血病患者P糖蛋白(P170)表达,并对阳性患者随机分组,用浙贝母散剂加联合化疗进行逆转多药耐药的临床研究.结果.浙贝母散剂在临床安全剂量下,与常规化疗方案合用,仍可逆转P170高表达;浙贝母散剂与急性白血病(AL)常规化疗方案合用可以降低骨髓原始细胞百分比,有可能提高临床治疗完全缓解率.结论.浙贝母散剂可能成为一种安全有效的多药耐药逆转剂,在P170高表达的急性白血病中有较大的临床意义及推广价值.

Clinical Trial of Fritillaria Thunbergii Bulb Powder for Reversing Multidrug Resistance in the Patients with Acute Leukemia

Objective To initially investigate the effects of the combination of Fritillaria Thunbergii Bulb Powder (FTBP) and chemotherapeutics for reversing the higher expression of P 170 and its clinical prospect of application. Methods The expression of P 170 in the patients with acute leukemia was detected by flow cytometry, and the P 170 positive cases were treated with the combination of FTBP and chemotherapeutics in order to carry out the clinical study of reversing multidrug resistance.Results It was found that the higher expression of P 170 could be reversed by the combination of FTBP and routine chemotherapeutics in which the FTBP was used in a clinically safe dose. The combination use of FTBP with routine chemotherapeutics could decrease the percentage of the marrow primordial cells and might increase the clinical complete remission ratio.Conclusion FTBP may become a safe and effective drug for reversing multidrug resistance, and has a rather big value to be promoted into clinical application for treating the patients with acute leukemia characterized by higher expression of P 170 .